MARKET

PIRS

PIRS

Pieris Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.43
-0.03
-0.55%
After Hours: 5.43 0 0.00% 16:00 09/17 EDT
OPEN
5.44
PREV CLOSE
5.46
HIGH
5.62
LOW
5.38
VOLUME
445.15K
TURNOVER
--
52 WEEK HIGH
6.04
52 WEEK LOW
2.390
MARKET CAP
268.20M
P/E (TTM)
-7.0355
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of PIRS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

PIRS News

  • Pieris Pharmaceuticals (PIRS) Investor Presentation - Slideshow
  • Seeking Alpha - Article.09/05 15:51
  • Pieris Pharma announces management changes
  • seekingalpha.09/03 17:34
  • Pieris Pharmaceuticals Announces Changes to Senior Management Team
  • ACCESSWIRE.09/03 12:30
  • Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences
  • ACCESSWIRE.08/29 13:00

More

Industry

Biotechnology & Medical Research
-0.22%
Pharmaceuticals & Medical Research
+0.42%

Hot Stocks

Name
Price
%Change

About PIRS

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.
More

Webull offers Pieris Pharmaceuticals Inc (PIRS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.